Teacher Retirement System of Texas Has $26.96 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Teacher Retirement System of Texas increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 137.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 64,200 shares of the company's stock after purchasing an additional 37,163 shares during the quarter. Teacher Retirement System of Texas owned approximately 0.08% of IDEXX Laboratories worth $26,961,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Norges Bank acquired a new stake in shares of IDEXX Laboratories in the fourth quarter worth $412,258,000. GAMMA Investing LLC lifted its stake in shares of IDEXX Laboratories by 59,810.7% in the first quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock worth $3,856,950,000 after buying an additional 916,898 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of IDEXX Laboratories in the fourth quarter worth $156,412,000. William Blair Investment Management LLC lifted its stake in shares of IDEXX Laboratories by 701.6% in the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after buying an additional 369,471 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in shares of IDEXX Laboratories by 221.3% in the fourth quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company's stock worth $182,459,000 after buying an additional 303,966 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director directly owned 1,801 shares of the company's stock, valued at approximately $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.98% of the company's stock.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of analyst reports. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target on the stock. Leerink Partners raised their price target on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. Finally, Stifel Nicolaus raised their price target on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a research report on Wednesday, July 2nd. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and a consensus target price of $558.11.

IDEXX Laboratories Price Performance

IDXX stock traded down $1.45 during trading on Monday, hitting $545.56. 448,551 shares of the stock traded hands, compared to its average volume of 646,147. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $549.52. The stock has a market cap of $43.87 billion, a price-to-earnings ratio of 50.42, a P/E/G ratio of 3.99 and a beta of 1.54. The company has a 50 day simple moving average of $512.86 and a 200 day simple moving average of $456.11. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same period last year, the firm posted $2.71 EPS. The firm's quarterly revenue was up 3.6% on a year-over-year basis. Equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.